Ace inhibitor acute kidney injury
Pro Research Analysisby 
Searched over 200M research papers
ACE Inhibitors and Acute Kidney Injury: A Comprehensive Review
Introduction to ACE Inhibitors and Acute Kidney Injury
Angiotensin-converting enzyme inhibitors (ACE inhibitors) are widely used to manage hypertension and heart failure. However, their use has been associated with an increased risk of acute kidney injury (AKI), particularly during periods of intercurrent illness or surgical procedures. This article synthesizes recent research findings on the relationship between ACE inhibitors and AKI, highlighting key insights and clinical implications.
Increased Hospital Admissions for AKI with ACE Inhibitor Use
Prescribing Trends and AKI Rates
A longitudinal ecological study in England found a significant association between increased prescribing of ACE inhibitors and angiotensin receptor antagonists (ARAs) and rising hospital admissions for AKI. From 2007 to 2011, AKI admission rates increased by 51.6%, while ACE-I/ARA prescribing rates rose by 15.8%. The study estimated that up to 15% of the increase in AKI admissions could be attributed to higher prescribing rates of these medications .
Post-AKI Outcomes and ACE Inhibitor Continuation
Risks and Benefits of Continuing ACE Inhibitors Post-AKI
Research comparing patients who continued versus those who stopped ACE inhibitors after an AKI episode revealed mixed outcomes. In England, continuing ACE inhibitors was associated with a higher risk of death but no significant difference in heart failure, subsequent AKI, or stroke. Conversely, in Sweden, stopping ACE inhibitors did not increase the risk of death and was associated with a lower incidence of stroke . Another study found that continuing ACE inhibitors post-AKI was linked to lower long-term mortality but a higher risk of hospitalization for renal causes .
ACE Inhibitors in Specific Clinical Settings
Preoperative Use in Cardiac Surgery
A study on patients undergoing coronary artery bypass grafting (CABG) found that preoperative use of ACE inhibitors was associated with a reduced incidence of postoperative AKI. The protective effect was significant even after adjusting for various risk factors, suggesting a potential benefit of ACE inhibitors in this surgical context .
Impact on COVID-19 Patients
In patients with severe COVID-19, chronic use of ACE inhibitors was associated with an increased risk of AKI. The study highlighted that ACE inhibitor use could predict the development of acute respiratory failure, emphasizing the need for careful monitoring in this patient population .
Risk Factors and Combinations Leading to AKI
Hypertensive Inpatients and Diuretic Combinations
A study on hypertensive inpatients treated with ACE inhibitors and diuretics identified chronic kidney disease and poor cardiac function as major risk factors for AKI. The combination of thiazide diuretics and aldosterone antagonists posed a higher risk of AKI compared to other diuretic combinations .
Pediatric Considerations
In neonates and infants with congenital heart disease, ACE inhibitor use was associated with a significant incidence of AKI. Concomitant use of tolvaptan and Down syndrome were identified as independent risk factors, suggesting the need for cautious use of ACE inhibitors in this vulnerable population .
Conclusion
The relationship between ACE inhibitors and AKI is complex and influenced by various factors, including patient demographics, comorbidities, and concurrent medications. While ACE inhibitors can offer significant benefits in managing hypertension and heart failure, their potential to induce AKI necessitates careful patient selection and monitoring. Further research is needed to optimize the use of ACE inhibitors in patients at risk of AKI and to develop strategies to mitigate this risk.
Sources and full results
Most relevant research papers on this topic
DOI